Therefore, IGFBP3 could play an indirect role in HCC development by reducing IGF1 bioavailability to its receptor, and could be a molecular target for novel therapeutic strategies in HCC patients. The gene discussed is IGFBP3; the disease is hepatocellular carcinoma.